Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Projected cost-effectiveness of new vaccines for adolescents in the United States.

Ortega-Sanchez IR, Lee GM, Jacobs RJ, Prosser LA, Molinari NA, Zhang X, Baine WB, McCauley MM, Miller T; Working Group on Leading Economic Issues for New Vaccine for Adolescents.

Pediatrics. 2008 Jan;121 Suppl 1:S63-78. doi: 10.1542/peds.2007-1115H. Review.

PMID:
18174323
2.

Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.

Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE; Active Bacterial Core Surveillance Team.

Clin Infect Dis. 2008 Jan 1;46(1):1-13. doi: 10.1086/524041.

PMID:
18171206
3.

Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies.

Anonychuk AM, Tricco AC, Bauch CT, Pham B, Gilca V, Duval B, John-Baptiste A, Woo G, Krahn M.

Pharmacoeconomics. 2008;26(1):17-32. Review.

PMID:
18088156
4.

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V.

Clin Ther. 2008 Feb;30(2):341-57. doi: 10.1016/j.clinthera.2008.02.003. Review.

PMID:
18343273
5.

New vaccines against otitis media: projected benefits and cost-effectiveness.

O'Brien MA, Prosser LA, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M, Hinrichsen VL, Mehta J, Colborn DK, Lieu TA.

Pediatrics. 2009 Jun;123(6):1452-63. doi: 10.1542/peds.2008-1482.

PMID:
19482754
6.

Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.

Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ.

Vaccine. 2008 Jun 2;26(23):2841-8. doi: 10.1016/j.vaccine.2008.03.046. Epub 2008 May 6.

PMID:
18462851
7.

Economic evaluation of human papillomavirus vaccination in developed countries.

Brisson M, Van de Velde N, Boily MC.

Public Health Genomics. 2009;12(5-6):343-51. doi: 10.1159/000214924. Epub 2009 Aug 11. Review.

PMID:
19684446
8.

Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group.

Newall AT, Kelly H, Harsley S, Scuffham PA.

Pharmacoeconomics. 2009;27(6):439-50. doi: 10.2165/00019053-200927060-00001. Review.

PMID:
19640008
9.

Epidemiological and economic impact of human papillomavirus vaccines.

Jeurissen S, Makar A.

Int J Gynecol Cancer. 2009 May;19(4):761-71. doi: 10.1111/IGC.0b013e3181a130c0.

PMID:
19509585
10.

The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity.

Armstrong GL, Billah K, Rein DB, Hicks KA, Wirth KE, Bell BP.

Pediatrics. 2007 Jan;119(1):e22-9.

PMID:
17200247
11.

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

Annemans L, Rémy V, Oyee J, Largeron N.

Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006.

PMID:
19354343
12.

Economic aspects of vaccines and immunizations.

Hinman AR.

C R Acad Sci III. 1999 Nov;322(11):989-94. Review.

PMID:
10646095
13.

Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review.

Techakehakij W, Feldman RD.

Vaccine. 2008 Nov 18;26(49):6258-65. doi: 10.1016/j.vaccine.2008.09.036. Epub 2008 Oct 1. Review.

PMID:
18835313
14.

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.

Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A.

Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. Review.

15.

Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review.

Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G.

Pharmacoeconomics. 2009;27(2):127-47. doi: 10.2165/00019053-200927020-00004. Review. Erratum in: Pharmacoeconomics. 2009;27(4):354.

PMID:
19254046
16.

Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults.

Rosenthal P.

Hepatology. 2003 Jan;37(1):44-51. Review.

PMID:
12500187
17.

Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.

Kim SY, Goldie SJ.

Pharmacoeconomics. 2008;26(3):191-215. Review.

PMID:
18282015
18.
19.
20.

[Vaccination--value for money?].

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Kristiansen IS.

Tidsskr Nor Laegeforen. 2006 Oct 19;126(20):2670-3. Norwegian.

Supplemental Content

Support Center